TAVR in 2023: Who Should Not Get It?

Sukhdeep Bhogal; Toby Rogers; Amer Aladin; Itsik Ben-Dor; Jeffrey E. Cohen; Christian C. Shults; Jason P. Wermers; Gaby Weissman; Lowell F. Satler; Michael J. Reardon; Steven J. Yakubov; Ron Waksman

doi:10.1016/j.amjcard.2023.01.040

TAVR in 2023: Who Should Not Get It?

Sukhdeep Bhogal, Toby Rogers, Amer Aladin, Itsik Ben-Dor, Jeffrey E. Cohen, Christian C. Shults, Jason P. Wermers, Gaby Weissman, Lowell F. Satler, Michael J. Reardon, Steven J. Yakubov, Ron Waksman

Research output: Contribution to journal › Review article › peer-review

Abstract

Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023.

Original language	English (US)
Pages (from-to)	1-18
Number of pages	18
Journal	American Journal of Cardiology
Volume	193
DOIs	https://doi.org/10.1016/j.amjcard.2023.01.040
State	Published - Apr 15 2023

Keywords

Aortic annulus
Bicuspid aortic valve
Severe aortic stenosis
Surgical aortic valve replacement
Transcatheter aortic valve replacement

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2023.01.040

Cite this

@article{ae19482ab7b9475793b352a6cc858e09,

title = "TAVR in 2023: Who Should Not Get It?",

abstract = "Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023.",

keywords = "Aortic annulus, Bicuspid aortic valve, Severe aortic stenosis, Surgical aortic valve replacement, Transcatheter aortic valve replacement",

author = "Sukhdeep Bhogal and Toby Rogers and Amer Aladin and Itsik Ben-Dor and Cohen, {Jeffrey E.} and Shults, {Christian C.} and Wermers, {Jason P.} and Gaby Weissman and Satler, {Lowell F.} and Reardon, {Michael J.} and Yakubov, {Steven J.} and Ron Waksman",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = apr,

day = "15",

doi = "10.1016/j.amjcard.2023.01.040",

language = "English (US)",

volume = "193",

pages = "1--18",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier",

}

TY - JOUR

T1 - TAVR in 2023

T2 - Who Should Not Get It?

AU - Bhogal, Sukhdeep

AU - Rogers, Toby

AU - Aladin, Amer

AU - Ben-Dor, Itsik

AU - Cohen, Jeffrey E.

AU - Shults, Christian C.

AU - Wermers, Jason P.

AU - Weissman, Gaby

AU - Satler, Lowell F.

AU - Reardon, Michael J.

AU - Yakubov, Steven J.

AU - Waksman, Ron

PY - 2023/4/15

Y1 - 2023/4/15

N2 - Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023.

AB - Since the first transcatheter delivery of an aortic valve prosthesis was performed by Cribier et al in 2002, the picture of aortic stenosis (AS) therapeutics has changed dramatically. Initiated from an indication of inoperable to high surgical risk, extending to intermediate and low risk, transcatheter aortic valve replacement (TAVR) is now an approved treatment for patients with severe, symptomatic AS across all the risk categories. The current evidence supports TAVR as a frontline therapy for treating severe AS. The crucial question remains concerning the subset of patients who still are not ideal candidates for TAVR because of certain inherent anatomic, nonmodifiable, and procedure-specific factors. Therefore, in this study, we focus on these scenarios and reasons for referring selected patients for surgical aortic valve replacement in 2023.

KW - Aortic annulus

KW - Bicuspid aortic valve

KW - Severe aortic stenosis

KW - Surgical aortic valve replacement

KW - Transcatheter aortic valve replacement

UR - http://www.scopus.com/inward/record.url?scp=85149235791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85149235791&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2023.01.040

DO - 10.1016/j.amjcard.2023.01.040

M3 - Review article

C2 - 36857839

AN - SCOPUS:85149235791

VL - 193

SP - 1

EP - 18

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

ER -

TAVR in 2023: Who Should Not Get It?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this